Indian generic drugmakers have launched a wave of affordable semaglutide products following the expiry of Novo Nordisk’s key patents, with over 50 brands expected in the coming months and prices slashed by up to 80% compared to the originator drugs. Sun Pharmaceutical led the charge at ₹750 ($8) per weekly injection, while Dr. Reddy’s launched both injectable and oral formulations. This development marks a historic shift in global access to GLP-1 therapies for diabetes and weight management, with Indian manufacturers now expanding to Canada, Turkey, and Brazil.
🇮🇳 Patent Expiry Triggers Generic Flood
Novo Nordisk’s key patent on semaglutide expired in India in March 2026, opening the floodgates for domestic manufacturers. According to Medical Dialogues (March 2026), more than 50 generic versions are lined up for launch — an unprecedented number for a complex biologic drug. Industry analysts note that this is relatively modest by Indian generic standards due to the technical complexity of manufacturing GLP-1 analogues, which require stringent quality controls.
Salil Kallianpur, an independent pharma consultant based in India, told CNBC (March 2026): “This is something that Indian generic players have been preparing for a very long time.” The complexity of making these drugs means fewer entrants than typical small-molecule generics, he noted.
💰 Price War: Up to 80% Below Novo’s Pricing
Sun Pharmaceutical launched its generic semaglutide injection at just ₹750 ($8) per weekly dose, or approximately ₹3,400 ($41) per month. This represents a dramatic 60–80% discount versus Novo Nordisk’s retail price of ₹8,800–10,000 ($106–$120) per month in India, depending on dosage strength.
Dr. Reddy’s Laboratories launched its generic semaglutide injection at around ₹4,200 per month for diabetes treatment, and separately introduced oral semaglutide tablets (branded Obeda) starting at approximately ₹97 ($1.16) per tablet, as reported by Navlin Daily (May 2026). The company’s CEO of Pharmaceutical Services, Deepak Sapra, stated the firm is targeting annual sales of 12 million semaglutide pens in the first year across all markets.
🌍 Indian Generics Expand Beyond Domestic Market
Indian manufacturers are not limiting themselves to the domestic market. Dr. Reddy’s received a Notice of Compliance from Health Canada in April 2026 for its generic semaglutide injection — the first generic version approved in Canada — and plans to expand to Turkey and Brazil this year, according to Business Wire (May 2026).
This global expansion leverages India’s established position as “the world’s pharmacy.” The country supplies approximately 20% of global off-patent medicines, as cited by CNBC (March 2026), and its diabetes population of ~100 million and obesity rates of nearly 25% make it both a critical manufacturing hub and a massive domestic market.
📊 Global Market Impact and Novo’s Response
While semaglutide remains patent-protected in the United States until 2032 (its largest market by revenue), patent expirations in India, Canada, Brazil, and China this year are already impacting Novo Nordisk’s revenue outlook. In February 2026, Novo warned that 2026 sales could decline by 5% to 13%, as reported by CNBC.
Novo Nordisk has responded by cutting prices in India and pursuing strategic partnerships to defend its market share. However, the combination of generic competition, US government pressure on drug pricing, and growing competition from Eli Lilly’s tirzepatide products is reshaping the global GLP-1 landscape.
🔍 What This Means for International Buyers
The Indian generic semaglutide boom presents significant opportunities for international pharmaceutical distributors and buyers:
- Massive cost savings: Indian generic GLP-1 drugs at 60–80% below originator pricing create new market access opportunities for price-sensitive healthcare systems globally.
- Multiple sourcing options: With 50+ brands expected, buyers have unprecedented choice in manufacturer, formulation (injection vs. oral), and pricing tiers.
- Global regulatory pathway: Indian manufacturers obtaining Health Canada and other regulatory approvals signals growing quality standards — look for WHO-GMP certified factories.
- Supply chain diversification: Indian-manufactured semaglutide offers an alternative supply source beyond the single-originator model, improving drug security.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- CNBC — “India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top” (March 2026)
- Medical Dialogues — “India’s Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch” (March 2026)
- eHealth Magazine — “Dr Reddy’s Gears Up for March Launch of Generic Semaglutide ‘Obeda’ in India” (February 2026)
- Navlin Daily — “Dr. Reddy’s Launches Oral Semaglutide Biosimilar in India Starting at $1.16 per Tablet” (May 2026)
- Business Wire — “Dr. Reddy’s Laboratories Launches its Generic Semaglutide Injection in Canada” (May 2026)
- Fierce Pharma — “With Novo’s semaglutide going off patent, Indian drugmakers set to launch their cheaper generics” (March 2026)
- Reuters — “Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible” (February 2026)
For more information, contact IMSDA at contact@indiamedicine.org.